Crossmark

A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy

Crossref DOI link: https://doi.org/10.1038/pcan.2015.59

Published Online: 2016-01-12

Published Print: 2016-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Armstrong, A J

Halabi, S

Healy, P

Lee, W R

Koontz, B F

Moul, J W

Mundy, K

Creel, P

Wood, S

Davis, K

Carducci, M A

Stein, M

Hobbs, C

Reimer, B

Nguyen, M

Anand, M

Bratt, L

Kim, S

Tran, P T

George, D J

,
License Information

Text and Data Mining valid from 2016-01-12

Version of Record valid from 2016-01-12
More Information

Article History

Received: 25 September 2015

Revised: 21 October 2015

Accepted: 17 November 2015

First Online: 12 January 2016

Competing interests

: This work has received research support from Pfizer and Sanofi (AJA, DJG), consulting with Pfizer and Sanofi (AJA, DJG, MAC), speaker’s bureau for Sanofi (DJG). The remaining authors declare no conflict of interest.

Document is current

Any future updates will be listed below